The Venture Codex

Participated · Seed · Nov 2022

Sarcura has developed a silicon chip technology with engraved microfluidic channels and integrated photonics to automate, miniaturize and add real-time control to cell therapy manufacturing. The cartridges are designed to enable robust engineering of CAR‑T and other cellular treatments, allowing scientists to control, manipulate and automate drug design in real time. The company positions its tech to reduce manufacturing costs and enhance control during cell selection and engineering. Sarcura cites a crowded pipeline of 1,400+ CAR‑T candidates and argues many will be unsustainable without lower-cost production tools. The team says the cartridges have multiple uses across cell therapy development and manufacturing workflows. The startup was formed two years ago and is based in Austria.